Schizophrenia/Psychosis

August 18th 2025

BioXcel Therapeutics advances BXCL501 for outpatient treatment of agitation in bipolar disorder and schizophrenia, receiving positive FDA feedback in its pre-sNDA meeting discussion.

August 15th 2025

AI chatbots pose significant mental health risks, often exacerbating issues like suicide, self-harm, and delusions, highlighting urgent regulatory needs.

August 11th 2025

UK study of "active ingredients" in early psychosis intervention is applicable to US programs, according to the codirector of Stanford's INSPIRE Clinic.

August 8th 2025

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.